On May 12th, Lilly announced the detailed results of the SURMUNT-5 study. This study is an open label phase 3b clinical trial to evaluate the effectiveness and safety of tirzepatide, a GLP/GLP-1 dual receptor agonist, and semaglutide, a GLP-1 single receptor agonist, in obese or overweight adults (without diabetes) with at least one complication (such as hypertension, dyslipidemia, obstructive sleep apnea, and cardiovascular disease). At week 72, tilpotide reached the primary endpoint and all five key secondary endpoints, demonstrating superiority over semaglutide throughout the entire trial. In the primary endpoint of the study, telapride achieved a 1.47-fold relative weight loss compared to semaglutide. According to research data based on treatment plan estimation goals, at week 72, the average weight loss rate achieved by telmisartan was 20.2%, while that of semaglutide was 13.7%. The average weight loss of the Tilpotide group was 22.8kg, and the average weight loss of the Smeaglutide group was 15.0kg.
Scan code to share